Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate

British Journal of Haematology

Volumn 152, Issue 6, 2011, Pages 758-765

  Blombäck, Margareta ^a   He, Shu ^a   Bark, Niklas ^a,b   Wallen, Håkan N ^a   Elg, Margareta ^c  

^a Department of Molecular Medicine and Surgery/Coagulation Research ^*  (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

FEIBA; Fibrin network; Thrombin inhibitors; Warfarin; Xa inhibitors

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTICOAGULANT AGENT; APIXABAN; AR H067637; AZD 0837; CALCIUM; FIBRIN; FONDAPARINUX; PHOSPHOLIPID; RECOMBINANT THROMBOPLASTIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; WARFARIN;

ARTICLE; BLOOD CLOTTING; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; HUMAN; HUMAN CELL; INTERNATIONAL NORMALIZED RATIO; MEMBRANE PERMEABILITY; POROSITY; PRIORITY JOURNAL; THREE DIMENSIONAL IMAGING; THROMBOCYTE POOR PLASMA;

AMIDINES; ANTICOAGULANTS; AZETIDINES; BLOOD COAGULATION FACTORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRIN; HUMANS; INTERNATIONAL NORMALIZED RATIO; MICROSCOPY, CONFOCAL; PERMEABILITY; POLYSACCHARIDES; POROSITY; PYRAZOLES; PYRIDONES; WARFARIN;

EID: 79952004141     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08546.x     Document Type: Article

References (26)

1. Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M. & Palareti, G. (2008) Pharmacology and management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 133, 160S-198S.
2. Blombäck, B. & Bark, N. (2004) Fibrinopeptides and fibrin gel structure. Biophysical Chemistry, 112, 147-151.
3. Blombäck, B., Carlsson, K., Fatah, K., Hessel, B. & Procyk, R. (1994) Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thrombosis Research, 75, 521-538.
4. Boos, C.J. & Lip, G.Y.H. (2006) Ximelagatran: an eulogy. Thrombosis Research, 118, 301-304.
5. Borris, L.C. (2009) Rivaroxaban, a new, oral, direct factor Xa inhibitor for thromboprophylaxis after major joint artroplasty. Expert Opinion on Pharmacotherapy, 10, 1083-1088.
6. Carreiro, J. & Ansell, J. (2008) Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict. Expert Opinion on Investigational Drugs, 17, 1937-1945.
7. Collet, J.P., Park, D., Lesty, C., Soria, J., Soria, C., Montalescot, G. & Weisel, J.W. (2000) Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arteriosclerosis, Thrombosis, and Vascular Biology, 20, 1354-1361.
8. Connolly, S.J., Ezekowitz, M.D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P.A., Themeles, E., Varrone, J., Wang, S., Alings, M., Xavier, D., Zhu, J., Diaz, R., Lewis, B.S., Darius, H., Diener, H.C., Joyner, C.D. & Wallentin, L. (2009) RE-LY Steering Committee and Investigators: Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 361, 1139-1151.
9. Deinum, J., Mattsson, C., Inghardt, T. & Elg, M. (2009) Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637. Thrombosis and Haemostasis, 101, 1051-1059.
10. Elg, M., Carlsson, S. & Gustafsson, D. (2001a) Effect of Activated Prothrombin Complex Concentrate or recombinant Factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thrombosis Research, 101, 145-157.
11. Elg, M., Carlsson, S. & Gustafsson, D. (2001b) Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anaesthetized rats and rabbits. Thrombosis Research, 101, 159-170.
12. He, S., Cao, H., Antovic, A. & Blombäck, M. (2005a) Modifications of flow measurement to determine fibrin gel permeability and the preliminary use in research and clinical materials. Blood Coagulation and Fibrinolysis, 16, 61-67.
13. He, S., Ekman, J.G. & Hedner, U. (2005b) The effect of platelets on fibrin gel structure formed in the presence of recombinant factor VIIa in hemophilia plasma and in plasma from a patient with Glanzmann thromasthenia. Journal of Thrombosis and Haemostasis, 3, 272-279.
14. He, S., Ezban, M., Bark, N., Persson, E. & Hedner, U. (2009) Fibrin gel structure obtained with a FVIIa analogue with enhanced FXa-activating potential in haemophilia. Thrombosis and Haemostasis, 102, 790-792.
15. He, S., Blombäck, M., Bark, N., Johnsson, H. & Wallen, N.H. (2010) The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis. Thrombosis and Haemostasis, 103, 1076-1084.
16. Hirsh, J., Bauer, K.A., Donati, M.B., Gould, M., Samama, M.M. & Weitz, J.I. (2008) Parenteral anticoagulants. Chest, 133, 141S-59S.
17. Lip, G.Y.H., Rasmussen, L.H., Olsson, S.B., Jensen, E.C., Persson, A.L., Eriksson, U., Wåhlander, K.F. & on behalf of the Steering Committee. (2009) Oral direct inhibitor AZD 0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. European Heart Journal, 30, 2832-2834.
18. Negrier, C., Dargaud, Y. & Bordet, J.C. (2006) Basic aspects of bypassing agents. Haemophilia, 12(Suppl 6), 48-53.
19. Nishio, H., Ieko, M. & Nakabayashi, T. (2008) New therapeutic option for thromboembolism-dabigatran etexilate. Expert Opinion on Pharmacotherapy, 9, 2509-2517.
20. Pehrsson, S., Johansson, K., Kjaer, M. & Elg, M. (2010) Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats. Thrombosis and Haemostasis, 104, 1242-1249.
21. Raghavan, N., Frost, C.E., Yu, Z., He, K., Zhang, H., Humphreys, W.G., Pinto, D., Chen, S., Bonacorsi, S., Wong, P.C. & Zhang, D. (2009) Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metabolism and Disposition, 37, 74-81.
22. Schulman, S. & Bijsterveld, N.R. (2007) Anticoagulants and their reversal. Transfusion Medicine Reviews, 21, 37-48.
23. Shantsila, E. & Lip, G.Y.H. (2008) Apixaban, an oral, direct inhibitor of activated Factor Xa. Current Opinion in Investigational Drugs, 9, 1020-1033.
24. Váradi, K., Negrier, C., Berntorp, E., Astermark, J., Bordet, C., Morfini, M., Linari, S., Schwartz, H.P. & Turecek, P.L. (2003) Monitoring the bioavailability of FEIBA with a thrombin generation assay. Journal of Thrombosis and Haemostasis, 1, 2374-2380.
25. Weitz, J.I., Hirsh, J. & Samama, M.M. (2008) New Antithrombotic Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 133, 234S-256S.
26. Wojcik, C., Schymik, M.L. & Cure, E.G. (2009) Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy. International Journal of Emergency Medicine, 2, 217-225.